New drug targets brain inflammation in Alzheimer's
NCT ID NCT06745583
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks. Researchers will also check if it reduces brain inflammation using special brain scans. Participants must have stable Alzheimer's symptoms and be on steady medications for at least 8 weeks before joining.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD, MODERATE, OR SEVERE ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
-
Tri-Service General Hospital
RECRUITINGTaipei, 11490, Taiwan